Valuation: Portage Biotech Inc

Market Cap 4.54M 3.93M 3.68M 3.36M 6.32M 433M 6.43M 43.18M 16.92M 217M 17.04M 16.67M 723M P/E 2025
-1.62x
P/E 2026 -0.08x
Enterprise Value 4.17M 3.61M 3.38M 3.09M 5.81M 398M 5.91M 39.67M 15.54M 199M 15.66M 15.32M 664M EV / Sales 2025
-
EV / Sales 2026 72,539,474x
Free-Float
-
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 38 2025-08-02
Director of Finance/CFO 39 2025-10-23
President 56 2026-07-15
Director TitleAgeSince
Director/Board Member 38 2025-08-02
Chairman 56 2025-09-02
Director/Board Member 69 2025-09-24
Change 5-day change 1-year change 3-year change Capi.($)
-0.72%+2.71%+5.66%+15.52% 50.03B
-0.69%+6.25%+492.36%+585.40% 44.36B
+0.08%+11.23%+23.99%+81.74% 40.82B
+0.76%+6.85%+35.40%+10.92% 39.83B
+4.73%+15.53%+26.95%+54.62% 32.51B
-0.41%+4.08% - - 16.85B
+0.51%+5.29%+34.62%+126.87% 16.81B
-0.20%+3.19%+5.18%+18.55% 14.05B
+1.81%+20.45%+89.35%+31.49% 13.22B
Average +0.72%+279.97%+89.19%+115.64% 29.83B
Weighted average by Cap. +0.63%+295.32%+108.20%+139.50%

Financials

2025 2026
Net sales - 0.1 0.08 0.08 0.07 0.14 9.25 0.14 0.92 0.36 4.63 0.36 0.36 15.45
Net income -6.77M -5.86M -5.49M -5.01M -9.43M -645M -9.58M -64.37M -25.22M -323M -25.41M -24.85M -1.08B -38.63M -33.47M -31.34M -28.59M -53.81M -3.68B -54.71M -367M -144M -1.84B -145M -142M -6.15B
Net Debt -1.67M -1.45M -1.35M -1.24M -2.33M -159M -2.37M -15.89M -6.22M -79.73M -6.27M -6.13M -266M -369K -320K -299K -273K -514K -35.19M -523K -3.51M -1.38M -17.62M -1.39M -1.36M -58.77M
Logo Portage Biotech Inc
Portage Biotech Inc. develops pharmaceutical and biotech products through to clinical proof of concept focusing on unmet clinical needs. After proof of concept, the Company will look to sell or license the products to various pharmaceutical companies for further development through to commercialization. The Company's research and development work is primarily carried out through approximately two subsidiaries, including Portage Pharmaceuticals Ltd (PPL) and Biohaven Pharmaceutical Holding Company Limited (Biohaven). The Company also holds interests in Sentien Biotechnologies Inc., a regenerative medicine company. PPL focuses on discovering and developing cell permeable peptide (CPP) therapies to normalize gene expression, restore function and improve medical outcomes. Biohaven is engaged in the identification and development of glutamatergic agents for treatment-resistant neuropsychiatric disorders. Its product pipeline includes PPL-003, BHV-0223 and BHV-4157.
Employees
-